https://scholars.lib.ntu.edu.tw/handle/123456789/525035
Title: | New biological approaches in asthma: DNA-based therapy | Authors: | LI-CHIEH WANG JYH-HONG LEE YAO-HSU YANG YU-TSAN LIN BOR-LUEN CHIANG |
Issue Date: | 2007 | Journal Volume: | 14 | Journal Issue: | 15 | Start page/Pages: | 1607-1618 | Source: | Current Medicinal Chemistry | Abstract: | Asthma is characterized by airway inflammation, bronchial hyper-responsiveness, and reversible airway obstruction. Medications for asthma include corticosteroids, β2-adrenergic receptor agonists, chromones, methylxanthines, and leukotriene modifiers. Despite these advances in therapy, many symptoms are not well controlled. Since asthma is a chronic airway inflammation with a bias towards a type 2 T helper (Th2) cell response, some new approaches are targeted towards the Th2 inflammation pathway. These include anti-IgE therapy, anti-Th2 cytokine therapy, and therapies aiming at increasing Th1 cytokines. This article will focus on DNA-based therapy, a novel therapeutic strategy for asthma. Immunostimulatory gene therapy using CpG oligodeoxynucleotides with central deoxycytidyl-deoxyguanosine (CpG) dinucleotide, in which the cytosine nucleobase is unmethylated, can stimulate the innate immunity and augment Th1 response. With DNA gene therapy, genes can be introduced to target Th1 cytokines or other mediators in the airway in order to counteract Th2 inflammation in asthma. Also, antisense oligonucleotides can target mRNA species of interest in asthma. Through these therapies, we can expect long-lasting effects, better control of symptoms, and reducing medication in the future. ? 2007 Bentham Science Publishers Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34347341760&doi=10.2174%2f092986707780830961&partnerID=40&md5=6d73b02ba0c3650945bd4c81375efa1b https://scholars.lib.ntu.edu.tw/handle/123456789/525035 |
ISSN: | 0929-8673 | DOI: | 10.2174/092986707780830961 | SDG/Keyword: | adenovirus vector; antiasthmatic agent; antisense oligodeoxynucleotide; beta adrenergic receptor stimulating agent; chromone derivative; CpG oligodeoxynucleotide; cytokine receptor antagonist; eotaxin; epi 2010; FAS ligand; Flt3 ligand; galectin 3; gamma interferon; glucocorticoid; interleukin 1 receptor blocking agent; interleukin 10; interleukin 12; interleukin 18; interleukin 4 receptor blocking agent; interleukin 5; iss 1018; leukotriene derivative; liposome; methylxanthine derivative; oligodeoxynucleotide phosphorothioate; omalizumab; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; polylysine; transforming growth factor beta; unclassified drug; unindexed drug; aerosol; allergy; asthma; autoimmune disease; blood clotting disorder; blood clotting time; cardiovascular disease; clinical trial; complement activation; disease exacerbation; drug distribution; drug formulation; drug half life; drug safety; drug structure; drug targeting; drug tolerability; gene targeting; gene therapy; genetic transfection; human; hypotension; immunotherapy; nebulizer; nonhuman; nonviral gene delivery system; review; RNA interference; side effect; structure analysis; Th1 cell; Th2 cell; viral gene delivery system; Adjuvants, Immunologic; Animals; Asthma; DNA; Gene Therapy; Humans; Oligonucleotides; Oligonucleotides, Antisense; RNA Interference; RNA, Small Interfering |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.